Amgen stock: At EUR 389.28, Amgen stock gains 2.27 percent

Published on 10/21/2026 at 15:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Thirty analysts set a USD 387.93 target on October 18, 2026. Amgen stock costs EUR 389.28 on October 21, 2026, up 2.27 percent versus Xetra close.

Amgen gains 2.27 percent

MarketBeat reported a USD 387.93 average target from 30 analysts on October 18, 2026.
Amgen is scheduled to report its next results on November 3, 2026.
Amgen stock costs EUR 389.28 at Lang & Schwarz on October 21, 2026 at 3:40 p.m. CEST, 2.27 percent above the Xetra close of October 19, 2026.

Extreme Makroaufnahme einer gefrorenen transparenten Flüssigkeit mit feinen Eiskristallen in einem Glasfläschchen — Amgen Inc. (ISIN US0311621009) veranschaulicht diese Makroaufnahme einer gefrorenen Wirkstofflösung im Glasfläschchen, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) is covered by a USD 387.93 average 12-month target from 30 analysts, according to MarketBeat on October 18, 2026. At Lang & Schwarz, the stock was trading at EUR 389.28 on October 21, 2026 at 3:40 p.m. CEST, up 2.27 percent versus the Xetra close of October 19, 2026 at EUR 380.65.

Analysts set a USD 387.93 target

MarketBeat said the consensus was Hold across 30 analysts on October 18, 2026, including 16 Hold ratings, 10 Buy ratings, three Sell ratings and one Strong Buy rating. The USD 387.93 average target lies 11.42 percent below Amgen's Nasdaq price of USD 437.96 at 9:54 a.m. EDT on October 21, 2026.

Stock sits 2.03 percent below high

Amgen traded in a USD 288.00 to USD 447.03 52-week range as of October 21, 2026, leaving the Nasdaq price 2.03 percent below the high. The company's market capitalization was USD 236.8 billion, while volume stood at 182,908 shares at 9:54 a.m. EDT on October 21, 2026.

Next earnings date is November 3

MetaCap lists November 3, 2026 as Amgen's next earnings date and cites a consensus earnings-per-share estimate of USD 5.72. The schedule gives the market a dated event after the latest quote, while the current Nasdaq valuation stood at 27.26 times earnings on October 21, 2026.

Comparison with peers on October 21, 2026

Amgen: plus 2.27 percent, P/E 27.26, market capitalization USD 236.8 billion.
Gilead Sciences (Nasdaq, USD): minus 1.29 percent, P/E minus 58.05, market capitalization USD 191.6 billion.
Vertex Pharmaceuticals (Nasdaq, USD): plus 0.29 percent, P/E 30.07, market capitalization USD 130.8 billion.

Euro quote versus Xetra close

The euro quotation was EUR 8.63 above the Xetra close of October 19, 2026. Amgen's Nasdaq price remained below its 52-week high at the latest October 21, 2026 update. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.